Chinese Expert Consensus on Second-line Treatment for Non-small Cell Lung Cancer with Negative Driver Gene Mutations

TL;DR

This paper presents a Chinese expert consensus on second-line treatments for non-small cell lung cancer patients without driver gene mutations.

Contribution

The paper provides a unified expert consensus for second-line treatment options in China for NSCLC patients with negative driver gene mutations.

Findings

Immune checkpoint inhibitors offer new treatment options for patients with driver gene-negative NSCLC.

Current second-line treatments have limited efficacy, highlighting the need for more effective therapies.

The consensus is based on clinical evidence and expert discussion to guide treatment decisions.

Abstract

对于驱动基因阴性的晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）患者而言，既往化疗一直都是标准治疗选择，而免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）的加入为这部分患者提供了新的治疗选择。目前一线治疗可以选择化疗、抗血管生成药物或免疫治疗。尽管初始治疗能获得一定的有效率，但仍不可避免地会出现疾病进展或治疗失败，二线及以上治疗疗效差，患者预后不佳，临床上需要更多有效的二线治疗药物。中国临床肿瘤学会非小细胞肺癌专家委员会组织呼吸科、肿瘤科、病理科专家对驱动基因阴性人群临床研究证据进行了深入探讨，根据专家组讨论后广泛认可的临床诊疗经验，对驱动基因阴性NSCLC患者二线治疗制定了统一的专家共识，可作为中国临床医师选择驱动基因阴性NSCLC二线治疗的指导依据。

Evidence categories of diagnosis and treatment guidelines of Chinese Society of Clinical Oncology

Figures